Pixium Vision Aktie [WKN DE: A116CC / ISIN: FR0011950641]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Pixium Vision SA

22.02.22		Pixium Vision announces its unaudited financial results for 2021 and provides a business update (GlobeNewswire)
27.01.22		Pixium Vision announces the publication in Nature Communications of peer-reviewed clinical data demonstrating the clinical benefit of the Prima System in Dry AMD patients (GlobeNewswire)
06.01.22		Pixium Vision to attend BIOMED EVENT® by Invest Securities on January 26, 2022 (GlobeNewswire)
14.12.21		Pixium Vision to attend 11th Annual LifeSci Partners Corporate Access Event (GlobeNewswire)
08.12.21		Pixium Vision gaining confidence in execution timeline of the PRIMAvera pivotal trial following first patient implantation in the UK (GlobeNewswire)
25.11.21		Pixium Vision to present at BTIG’s Ophthalmology Day (GlobeNewswire)
08.11.21		Pixium Vision to present at the 3rd edition of Investir Day in Paris, November 2021 (GlobeNewswire)
22.10.21		Pixium Vision announces its cash position at 30 September 2021 and provides an update on its activities and financial outlook until the end of 2022 (GlobeNewswire)
13.10.21		Pixium Vision announces positive long-term follow-up scientific data on PRIMA implant from Prima System French feasibility study (GlobeNewswire)
02.06.21		Pixium Vision announces business update and key upcoming milestones to deliver on its business plan (GlobeNewswire)
10.05.21		General Meeting of 27 May 2021 Procedures for participating (GlobeNewswire)
21.04.21		Pixium Vision receives HealthTech Award for Prima System at the MedTech Forum (GlobeNewswire)
19.04.21		Pixium Vision announces the drawdown of a further tranche, with a nominal value of €1.5 million, under the financing contract with ESGO (GlobeNewswire)
18.04.21		Pixium Vision announces its cash position at 31 March 2021 and provides an update on its activities and financial outlook until the end of 2021. (GlobeNewswire)
07.04.21		Pixium Vision announces first patient successful implantation in Prima System pivotal trial PRIMAvera (GlobeNewswire)
03.04.21		Termination of the business combination with Second Sight Medical Products, Inc. (GlobeNewswire)
09.03.21		Continuation of the business combination project between Pixium Vision et Second Sight Medical Products (GlobeNewswire)
19.02.21		Pixium Vision announces its financial results for 2020 and provides a business update (GlobeNewswire)
06.01.21		Pixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market (GlobeNewswire)
20.11.20		Pixium Vision receives French regulatory authority (ANSM) approval to initiate European PRIMAvera pivotal study of Prima System (GlobeNewswire)
22.10.20		Pixium Vision announces its cash position at 30 September 2020 (GlobeNewswire)
16.10.20		Pixium Vision Hosting Key Opinion Leader Webinar on the Prima System for Atrophic Dry Age-related Macular Degeneration (dry-AMD) (GlobeNewswire)
27.04.18		Pixium Vision’s Research Partner, Stanford University, to Present Advances on Bioelectronic PRIMA Platform Technology During ARVO 2018 (Businesswire)
25.01.18		Pixium Vision Completes World’s First Successful Activation in Human of PRIMA Bionic Vision System (Businesswire)
04.01.18		Pixium Vision receives FDA approval to begin human clinical study of its PRIMA sub-retinal implant in the US (Businesswire)
19.10.17		Pixium Vision Receives Approval for First-in-Human Clinical Trial of PRIMA, Its Miniaturized Sub-Retinal Implant (Businesswire)
22.11.16		Pixium Vision and Silamir, Honoured at Quai d’Orsay, during the Award Ceremony of Janus 2016 from French Institute of Design (Businesswire)
07.11.16		Pixium Vision Announces the First Successful Implantation and Activation of IRIS® II, 150 Electrode Bionic Vision System, in the UK (Businesswire)
27.10.16		Pixium Vision: Results for the First 9 Months of 2016 (Businesswire)
29.09.16		Pixium Vision announces an 11 million Euros bond financing facility (Businesswire)
12.09.16		Pixium Vision Receives Clinical Trial Approval from Spanish Ministry of Health for 150 Electrode Iris®II Bionic Vision System (Businesswire)
25.07.16		Pixium Vision announces CE market approval of IRIS®II, its first bionic vision system (Businesswire)
20.07.16		Pixium Vision First Half 2016 Financial Results and Business Update (Businesswire)
31.05.16		Pixium Vision Receives Clinical Trial Approval From UK Regulatory Authority for 150 Electrode IRIS®II Bionic Vision System (Businesswire)
31.05.16		Pixium Vision Receives Clinical Trial Approval from UK Regulatory Authority for 150 Electrode IRIS®II Bionic Vision System (Businesswire)
04.05.16		Pixium Vision and Research Partners Report Significant Progress on PRIMA, a Tiny Wireless Sub-Retinal Implant During ARVO - World's Largest Vision Research Annual Conference (Businesswire)
27.04.16		Pixium Vision Announces Its First Quarter 2016 Financial Update and a New Date for Its Annual General Meeting (Businesswire)
24.02.16		World Premiere: Pixium Vision Implants IRIS® II, First Epi-Retinal Implant with 150 Electrodes (Businesswire)
24.02.16		World Premiere: Pixium Vision Implants IRIS® II, First Epi-Retinal Implant with 150 Electrodes (Businesswire)
16.02.16		Pixium Vision Receives Approval from German Regulatory Authority to Implant 150 Electrode IRIS® II in Clinical Trial (Businesswire)
29.01.16		Pixium Vision 2015 Financial Results and Business Update (Businesswire)
20.01.16		Pixium Vision’s 2016 Financial Calendar (Businesswire)
07.01.16		Pixium Vision Announces Positive Preclinical Safety and Feasibility Data for PRIMA, a Tiny, Wireless Subretinal Implant (Businesswire)
04.01.16		Full Year Update on Pixium Vision’s Liquidity Agreement (Businesswire)
21.12.15		Pixium Vision files for CE Mark for IRIS®II, its first Vision Restoration System (Businesswire)
14.12.15		Pixium Vision Receives Approval from French Regulatory Authority to Implant IRIS® II in Clinical Study (Businesswire)
11.12.15		Pixium Vision Receives the 2016 Observeur Du Design Award for IRIS®, Its First Vision Restoration System (Businesswire)
29.10.15		Pixium Vision: Sales for the First 9 Months of 2015 (Businesswire)
28.10.15		Pixium Vision wins the 2015 Janus Healthcare prize from prestigious French Institute of Design (Businesswire)
21.10.15		Pixium Vision Implants Additional Patients in the European Clinical Trial of Its Epi-Retinal System IRIS® (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer Mobility-Aktie bricht ein: KTM steht vor Insolvenz

Pierer-Aktie bricht ein: KTM AG zahlt Dezember-Gehälter kommende Woche aus - SPÖ in Sorge um Beschäftigte, NEOS fordern Reformen

MicroStrategy-Gründer als Fürsprecher: Microsoft will über Bitcoin-Investitionen abstimmen

Solana Kurs Prognose: 300 US-Dollar noch in diesem Jahr?

BVB will Negativserie beenden: Entscheidendes Spiel gegen Dinamo Zagreb - BVB-Aktie gewinnt

GAZPROM geht für 2025 offenbar von Ende des Gastransit durch die Ukraine aus

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	29.11.2024 13:50
Kaufwert:	EUR
	Hinzufügen Speichern